Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pixantrone + Rituximab vs Gemcitabine + Rituximab in Aggressive B-cell NHL
NCT01321541Phase 3Completed
- Sponsor
- CTI BioPharma Corp.
- Start
- Apr 2011
- Primary completion
- Jun 2018
- Modality
- DNA Intercalators/Alkylators
- Countries
- 17
01
Overview
A Phase 3 trial of pixantrone in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), sponsored by CTI BioPharma Corp.. Started Apr 2011; status: completed.
02
Drugs
pixantrone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT01321541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01321541.